FDA: ‘No Convincing Evidence’ Hormones In Cosmetics Pose Health Risk
This article was originally published in The Rose Sheet
FDA says it continues to monitor the issue of estrogens and progesterone in cosmetic products; however, in a recently published study an agency scientist notes that to date, FDA has found “no convincing evidence” that cosmetics containing the substances pose health risks. Products surveyed largely were found to be labeled properly, belying concerns that consumers may be exposing themselves unwittingly.
You may also be interested in...
FDA’s Office of Cosmetics and Colors continues with surveys to detect the presence of controversial ingredients in cosmetics, including asbestos in talc-containing products. Office’s Deputy Director Patricia Hansen provides an overview at the Personal Care Products Council’s recent scientific summit.
Manufacturers of hair finishing sprays, no-rinse shampoos and personal fragrance products – eg, perfumes, colognes and body sprays – face significant reformulation challenges under a draft proposal from California’s Air Resources Board that contemplates fewer category impacts, but deeper VOC cuts, compared with previous considerations to help meet state-wide pollution-reduction goals.
Leadership assured analysts on 6 November that Coty's Professional Beauty and Brazilian businesses are strong performers of high interest to potential acquirers, unlike Younique. Coty recently sold its majority stake in the social selling company back to its founders at a price that raised eyebrows.